Evidence map›Paper›PMID 28590426›Full record

ArticleInternational journal of molecular sciences2017

Down's Syndrome and Triple Negative Breast Cancer: A Rare Occurrence of Distinctive Clinical Relationship.

Nandini Dey, Amy Krie, Jessica Klein, Kirstin Williams, Amanda McMillan, Rachel Elsey, Yuliang Sun, Casey Williams, Pradip De, Brian Leyland-Jones

Open access · goldAbstract readCase Reports
In one paragraph

Article in International journal of molecular sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Nandini DeyCenter for Precision Oncology, Department of Molecular and Experimental Medicine, Avera Cancer Institute, Sioux Falls, SD 57105, USA. nandini.dey@avera.org.
Amy KrieCenter for Precision Oncology, Department of Molecular and Experimental Medicine, Avera Cancer Institute, Sioux Falls, SD 57105, USA. Amy.Krie@avera.org.
Jessica KleinCenter for Precision Oncology, Department of Molecular and Experimental Medicine, Avera Cancer Institute, Sioux Falls, SD 57105, USA. Jessica.Klein@avera.org.
Kirstin WilliamsCenter for Precision Oncology, Department of Molecular and Experimental Medicine, Avera Cancer Institute, Sioux Falls, SD 57105, USA. Kirstin.Williams@avera.org.
Amanda McMillanCenter for Precision Oncology, Department of Molecular and Experimental Medicine, Avera Cancer Institute, Sioux Falls, SD 57105, USA. Amanda.McMillan@avera.org.
Rachel ElseyCenter for Precision Oncology, Department of Molecular and Experimental Medicine, Avera Cancer Institute, Sioux Falls, SD 57105, USA. Rachel.Elsey@avera.org.
Yuliang SunCenter for Precision Oncology, Department of Molecular and Experimental Medicine, Avera Cancer Institute, Sioux Falls, SD 57105, USA. Yuliang.Sun@avera.org.
Casey WilliamsCenter for Precision Oncology, Department of Molecular and Experimental Medicine, Avera Cancer Institute, Sioux Falls, SD 57105, USA. Casey.Williams@avera.org.
Pradip DeCenter for Precision Oncology, Department of Molecular and Experimental Medicine, Avera Cancer Institute, Sioux Falls, SD 57105, USA. Pradip.De@avera.org.
Brian Leyland-JonesCenter for Precision Oncology, Department of Molecular and Experimental Medicine, Avera Cancer Institute, Sioux Falls, SD 57105, USA. brian.leylandjones@avera.org.
Avera Health · USUniversity of South Dakota · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Down's syndrome (DS), the most common genetic cause of significant intellectual disability in children and adults is caused by the trisomy of either all or a part of human chromosome 21 (HSA21). Patients with DS mostly suffer from characteristic tumor types. Although individual patients of DS are at a higher risk for acute leukemia and testicular cancers, other types of solid tumors including breast cancers are mostly uncommon and have significantly lower-than-expected age-adjusted incidence rates. Except for an increased risk of retinoblastomas, and lymphomas, the risk of developing solid tumors has been found to be lower in both children and adults, and breast cancer was found to be almost absent (Hasle H., The Lancet Oncology, 2001). A study conducted in the United States found only one death when 11.65 were expected (Scholl T et al., Dev Med Child Neurol. 1982). A recent study examined mammogram reports of women with DS treated in the largest medical facility specifically serving adults with DS in the United States. It was found that only 0.7% women with DS had been diagnosed with breast cancers (Chicoine B et al., Intellect Dev Disabil. 2015). Here we describe a case of breast cancer in a 25-year-old patient with DS. The disease was presented as lymph node positive carcinoma with alterations of tumor suppressor genes characteristic to the triple negative breast cancer subtype. Comprehensive Genomic Profiling (CGP) revealed a wild-type status for

Indexed as

AdultAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorChromosomes, Human, Pair 21Comparative Genomic HybridizationDown SyndromeFemaleHumansImmunohistochemistryMutationPositron Emission Tomography Computed TomographyTriple Negative Breast NeoplasmsTrisomyBiomarkers, TumorDown’s syndromePI3K-mTOR pathwaytriple negative breast cancertumor suppressor genes

Identifiers

PMID28590426
PMCPMC5486041
OpenAlexW2622826923

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.